Rule of 7s for Lyme Meningitis

Why use it

Lyme meningitis and viral aseptic meningitis are clinically indistinguishable at presentation — both present with headache, fever, neck stiffness, and CSF lymphocytic pleocytosis. Empirical IV antibiotic therapy for Lyme carries cost and hospitalization burden, while withholding treatment in true Lyme meningitis risks neurological complications. Lyme serology takes days to return. The Rule of 7s provides an immediate, structured framework — applicable at the bedside without waiting for laboratory results — to guide empirical treatment decisions while serology is pending.

About

The Rule of 7s is a validated clinical decision tool developed by Avery and colleagues and published in Pediatrics in 2006 to help clinicians distinguish Lyme meningitis from other causes of aseptic meningitis in children presenting with CSF pleocytosis in Lyme-endemic areas. The rule is named after the three thresholds — all containing the number 7 — that predict Lyme meningitis with high sensitivity. The three criteria are: (1) CSF polymorphonuclear (PMN) percentage ≥ 70% (neutrophil predominance), which is somewhat counterintuitive but reflects the acute inflammatory response in early Lyme meningitis; (2) Duration of headache ≥ 7 days prior to presentation; and (3) Presence of a seventh cranial nerve (CN VII / facial nerve) palsy. Lyme meningitis is considered likely — and empirical antibiotic therapy with IV or oral doxycycline or ceftriaxone should be strongly considered — when ANY one of the three criteria is present. Conversely, if NONE of the three criteria are met, Lyme meningitis is unlikely and the clinician should evaluate for other causes of aseptic meningitis (e.g., enterovirus, herpes simplex virus, bacterial meningitis). In the derivation cohort (Avery 2006), the rule had sensitivity of 96% and specificity of 41% for Lyme meningitis at any criterion present. The rule is designed for use in CHILDREN in Lyme-endemic areas with documented CSF pleocytosis — its applicability in adults and non-endemic regions is less well established.

When to use

• Child (typically 1–18 years) presenting with CSF pleocytosis (WBC >5 cells/mm³) in a Lyme-endemic area during tick season (late spring through fall)
• Distinguishing Lyme meningitis from viral aseptic meningitis to guide empirical antibiotic therapy decisions
• When Lyme serology is pending and a treatment decision must be made within hours of lumbar puncture
• As part of a structured evaluation when any combination of headache, fever, and facial nerve palsy is present in a child from an endemic region
• NOT validated for adults — apply clinical judgment in adult patients
• NOT applicable in non-endemic areas where the pretest probability of Lyme meningitis is very low
• NOT a substitute for Lyme serology (ELISA + Western blot) — always send confirmatory testing

Formula

Pearls & pitfalls

• Lyme meningitis classically presents with lymphocytic pleocytosis, but EARLY disease may show PMN predominance (≥70% PMNs) — this is NOT a sign of bacterial meningitis in this context.
• The seventh cranial nerve palsy in Lyme disease is typically peripheral facial nerve palsy (Bell's palsy-like) — it is BILATERAL in up to 25% of Lyme CN VII cases, which is rare in idiopathic Bell's palsy.
• Lyme meningitis headache is typically of longer duration than viral meningitis — patients often present after 1–2 weeks of headache, whereas viral meningitis headache is often acute (days).
• The rule was derived in children from highly endemic areas (Philadelphia, USA) — in regions with very low Lyme prevalence, even all three criteria present may not raise the pretest probability sufficiently to treat empirically.
• Serology: the ELISA alone has a false-negative rate of ~10–15% in early Lyme meningitis — a negative ELISA does NOT exclude Lyme. Western blot (IgM + IgG) is required for confirmation.
• Tick attachment duration matters: Ixodes scapularis (deer tick) typically requires ≥36 hours of attachment to transmit Borrelia burgdorferi. A history of recent tick bite supports the diagnosis.
• CSF Lyme antibody testing (CXCL13, Lyme intrathecal antibody index) may improve diagnosis but is not widely available and is not part of the standard Rule of 7s framework.
• In children with CN VII palsy + CSF pleocytosis in an endemic area, the probability of Lyme approaches 90% — treat empirically even if other criteria are absent.
• The Rule of 7s performs best during Lyme season (May–November in Northeast USA, Upper Midwest). Cases presenting in December–March in endemic areas require more cautious interpretation.
• If bacterial meningitis cannot be excluded (e.g., toxic appearance, high CSF WBC >500, CSF glucose <40, positive Gram stain), add broad-spectrum antibiotics (ceftriaxone ± vancomycin) pending culture results regardless of Rule of 7s.

Next steps

0 Criteria Met (No "7" criteria present): Lyme meningitis is unlikely. Probability of Lyme meningitis is low. Investigate for viral aseptic meningitis (enterovirus PCR, HSV PCR, CSF culture). Empirical Lyme antibiotics are not indicated based on the rule alone, but clinical judgment and epidemiology must guide the final decision. Send Lyme serology to confirm. 1–3 Criteria Met (Any "7" criterion present): Lyme meningitis is possible/likely. Initiate empirical Lyme treatment while serology is pending: doxycycline 100 mg BID × 14–21 days (preferred ≥8 years); IV ceftriaxone 50–75 mg/kg/day × 14–21 days if severe neurological involvement or unable to take oral therapy; amoxicillin 50 mg/kg/day TID × 14–21 days (alternative <8 years). Send Lyme serology (ELISA + confirmatory Western blot). Monitor for clinical improvement and adjust based on serology results.

Evidence

Avery RA, Frank G, Glutting JJ, Eppes SC. Risk of Lyme meningitis as a function of age, sex, and clinical features. Pediatrics. 2006;117(1):1-7. PMID:16396848. Derivation cohort n=79 children with CSF pleocytosis in endemic area. Rule of 7s: sensitivity 96%, specificity 41%. Wormser GP et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: IDSA guidelines. Clin Infect Dis. 2006;43(9):1089-1134. PMID:17029130. Halperin JJ et al. Practice Parameter: treatment of nervous system Lyme disease. Neurology. 2007;69(1):91-102.

References

1. Avery RA, Frank G, Glutting JJ, Eppes SC. Risk of Lyme meningitis as a function of age, sex, and clinical features. Pediatrics. 2006;117(1):1-7. — link
2. Wormser GP et al. The clinical assessment, treatment, and prevention of Lyme disease: IDSA Practice Guidelines. Clin Infect Dis. 2006;43(9):1089-1134. — link
3. Halperin JJ et al. Practice Parameter: treatment of nervous system Lyme disease (an evidence-based review). Neurology. 2007;69(1):91-102. — link
4. Shapiro ED. Clinical practice: Lyme disease. N Engl J Med. 2014;370(18):1724-1731. — link